Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 6, 2013, Pages 3454-3457

  Dings, Ruud P M ^a   Haseman, Judith R ^a   Leslie, Dan B ^b   Luong, Mike ^b   Dunn, David L ^b   Mayo, Kevin H ^a  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bactericidal; Endotoxin neutralizing; Lipopolysaccharide; Peptide

Indexed keywords

BACTERICIDE; DODECAPEPTIDE SC4 1; DODECAPEPTIDE SC4 10; DODECAPEPTIDE SC4 11; DODECAPEPTIDE SC4 12; DODECAPEPTIDE SC4 2; DODECAPEPTIDE SC4 3; DODECAPEPTIDE SC4 4; DODECAPEPTIDE SC4 5; DODECAPEPTIDE SC4 6; DODECAPEPTIDE SC4 7; DODECAPEPTIDE SC4 8; DODECAPEPTIDE SC4 9; DODECAPEPTIDE SC4 DERIVATIVE; INTERLEUKIN 1; INTERLEUKIN 6; PIPERACILLIN PLUS TAZOBACTAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAM NEGATIVE SEPSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE DAMAGE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONFORMATION; PSEUDOMONAS INFECTION; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; CYTOKINES; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; MALE; MICE; PENICILLANIC ACID; PEPTIDE FRAGMENTS; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; MUS; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 84875974241     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.02.002     Document Type: Article

References (22)

1. B. Spellberg, J.H. Powers, E.P. Brass, L.G. Miller, and J.E. Edwards Jr. Trends in antimicrobial drug development: implications for the future Clin. Infect. Dis. 38 2004 1279 1286
2. R.P. Wenzel The antibiotic pipeline - challenges, costs, and values N. Engl. J. Med. 351 2004 523 526
3. X. Chen, R.P. Dings, I. Nesmelova, S. Debbert, J.R. Haseman, J. Maxwell, T.R. Hoye, and K.H. Mayo Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins J. Med. Chem. 49 2006 7754 7765
4. R.P. Dings, and K.H. Mayo A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents Acc. Chem. Res. 40 2007 1057 1065
5. R.P. Dings, J.R. Haseman, and K.H. Mayo Probing structure-activity relationships in bactericidal peptide betapep-25 Biochem. J. 414 2008 143 150
6. W.L. Maloy, and U.P. Kari Structure-activity studies on magainins and other host defense peptides Biopolymers 37 1995 105 122
7. K. Matsuzaki, S. Yoneyama, N. Fujii, K. Miyajima, K. Yamada, Y. Kirino, and K. Anzai Membrane permeabilization mechanisms of a cyclic antimicrobial peptide, tachyplesin I, and its linear analog Biochemistry 36 1997 9799 9806
8. D. Andreu, R.B. Merrifield, H. Steiner, and H.G. Boman N-terminal analogues of cecropin A: synthesis, antibacterial activity, and conformational properties Biochemistry 24 1985 1683 1688
9. K.H. Mayo, J. Haseman, E. Ilyina, and B. Gray Designed beta-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities Biochim. Biophys. Acta 1425 1998 81 92
10. P.M. Hwang, and H.J. Vogel Structure-function relationships of antimicrobial peptides Biochem. Cell Biol. 76 1998 235 246
11. K.H. Mayo, J. Haseman, H.C. Young, and J.W. Mayo Structure-function relationships in novel peptide dodecamers with broad-spectrum bactericidal and endotoxin-neutralizing activities Biochem. J. 349 2000 717 728
12. N.A. Lockwood, J.R. Haseman, M.V. Tirrell, and K.H. Mayo Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains Biochem. J. 378 2004 93 103
13. T. Calandra, B. Echtenacher, D.L. Roy, J. Pugin, C.N. Metz, L. Hultner, D. Heumann, D. Mannel, R. Bucala, and M.P. Glauser Protection from septic shock by neutralization of macrophage migration inhibitory factor Nat. Med. 6 2000 164 170
14. NNIS National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004 Am. J. Infect. Control. 32 2004 470 485
15. A.C. Gales, R.N. Jones, J. Turnidge, R. Rennie, and R. Ramphal Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin. Infect. Dis. 32 Suppl. 2 2001 S146 S155
16. A. Kim, C.A. Sutherland, J.L. Kuti, and D.P. Nicolau Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 27 2007 1490 1497
17. J.Y. Homma A new antigenic schema and live-cell slide agglutination procedure for the infrasubspecific serologic classification of Pseudomonas aeruginosa Jpn. J. Exp. Med. 46 1976 329 336
18. R.P. Dings, X. Chen, D.M. Hellebrekers, L.I. van Eijk, Y. Zhang, T.R. Hoye, A.W. Griffioen, and K.H. Mayo Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities J. Natl. Cancer Inst. 98 2006 932 936
19. R.P. Dings, Y. Yokoyama, S. Ramakrishnan, A.W. Griffioen, and K.H. Mayo The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin Cancer Res. 63 2003 382 385
20. N.A. Lockwood, and K.H. Mayo The future of antibiotics: bacterial membrane disintegrators Drugs Future 28 2003 911 923
21. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit. Care Med. 29 2001 1303 1310
22. M.P. Glauser, G. Zanetti, J.D. Baumgartner, and J. Cohen Septic shock: pathogenesis Lancet 338 1991 732 736